12,15 €
1,27 % gestern
L&S, 7. Oktober, 22:53 Uhr
ISIN
US68622P1093
Symbol
ORIC
Berichte

ORIC Pharmaceuticals Inc Aktie News

Neutral
GlobeNewsWire
etwa ein Monat alt
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 2, 2025 (the “Grant Date”), ORIC granted a total of 292,500 non-qualified stock options and 79,000 restricted stock units to ...
Neutral
Seeking Alpha
etwa ein Monat alt
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC ) Pharmaceuticals, Inc. Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants Jacob Chacko - President, CEO & Director Dominic Piscitelli - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst W...
Neutral
GlobeNewsWire
etwa ein Monat alt
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in September:
Neutral
GlobeNewsWire
etwa 2 Monate alt
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO). Dr. Brodbeck brings more than 25 years ...
Neutral
GlobeNewsWire
etwa 2 Monate alt
Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top-tier healthcare specialist investors across $125 million private placement financing and $119 million ATM issuances; Following recent financing ...
Neutral
GlobeNewsWire
2 Monate alt
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 (the “Grant Date”), ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two ne...
Neutral
GlobeNewsWire
3 Monate alt
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new n...
Neutral
GlobeNewsWire
4 Monate alt
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the “Grant Date”), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three ne...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen